Prophylactic efficacy of topical temporin A and RNAIII-inhibiting peptide in a subcutaneous rat pouch model of graft infection attributable to staphylococci with intermediate resistance to glycopeptides

Circulation

Volumn 108, Issue 6, 2003, Pages 767-771

  Cirioni, Oscar ^b   Giacometti, Andrea ^b   Ghiselli, Roberto ^b   Dell'Acqua, Giorgio ^a   Gov, Yael ^b   Kamysz, Wojciech ^b   Łukasiak, Jerzy ^b   Mocchegiani, Federico ^b   Orlando, Fiorenza ^b   D'Amato, Giuseppina ^b   Balaban, Naomi ^b   Saba, Vittorio ^b   Scalise, Giorgio ^b  

^a Arval Biological Laboratories   (Switzerland)

^b c/o Ospedale Regionale ^*

Author keywords

Grafting; Infection; Peptides; Vasculature

Indexed keywords

ANTIINFECTIVE AGENT; GLYCOPEPTIDE; RIFAMPICIN; RNAIII INHIBITING PROTEIN; TEMPORIN A; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BLOOD VESSEL PROSTHESIS; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; GRAFT INFECTION; INTERMETHOD COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS INFECTION; RAT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STRAIN DIFFERENCE; SUBCUTANEOUS TISSUE;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GLYCOPEPTIDES; IMPLANTS, EXPERIMENTAL; MALE; MICROBIAL SENSITIVITY TESTS; OLIGOPEPTIDES; POLYETHYLENE TEREPHTHALATES; PROTEINS; RATS; RATS, WISTAR; RIFAMPIN; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; SUBCUTANEOUS TISSUE; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 0043164919     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000083717.85060.16     Document Type: Article

References (42)

1. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilm: a common cause of persistent infections. Science. 1999;284:1318-1322.
2. Von Eiff C, Heilmann C, Peters G. New aspects in the molecular basis of polymer-associated infections due to staphylococci. Eur J Clin Microbiol Infect Dis. 1999;18:853-856.
3. Douglas JL, Cobbs CG. Prosthetic valve endocarditis. In: Kaye D, ed. Infective Endocarditis. New York: Raven Press; 1992:375-396.
4. Hancock REW. Artificial valve disease. In: Schlant RC, Alexander RW, O'Rourke RA, et al, eds. The Heart Arteries and Veins. New York: McGraw-Hill; 1994:1539-1545.
5. Maki DG. Infections caused by intravascular devices used for infusion therapy: pathogenesis, prevention and management. In: Bisno AL. Waldovogel FA. eds. Infections Associated With Indwelling Medical Devices. Washington, DC: American Society for Microbiology; 1994:155-212.
6. Stewart PS, Costerton JW. Antibiotic resistance of bacteria biofilm. Lancet. 2001;358:135-138.
7. Bergamini TM, Corpus RA Jr, McCurry TM, et al. Immunosuppression augments growth of graft-adherent Staphylococcus epidermidis. Arch Surg 1995;130:1345-1350.
8. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167-193.
9. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-532.
10. Henke PK, Bergamini TM, Rose SM, et al. Current opinion in prosthetic vascular graft infection. Am Surg. 1998;64:39-45.
11. Daschner FD, Kropec A. Glycopeptides in the treatment of staphylococcal infections. Eur J Clin Microbiol Infect Dis. 1995;14(suppl 1):S12-S17.
12. Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin Microbiol Rev. 2002;15:430-438.
13. Raad I, Alrahwan A, Rolston K. Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin Infect Dis. 1998;26:1182-1187.
14. Biavasco F, Vignaroli C, Varaldo PE. Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis. 2000;19:403-417.
15. McManus AT, Goodwin CW, Pruitt BA Jr. Observations on the risk of resistance with the extended use of vancomycin. Arch Surg. 1998;133:1207-1211.
16. Barie PS. Antibiotic-resistant gram-positive cocci: implications for surgical practice. World J Surg. 1998;22:118-126.
17. Sardelic F, Ao PY, Taylor DA, et al. Prophylaxis against Staphylococcus epidermidis vascular graft infection with rifampicin-soaked, gelatin-sealed Dacron. Cardiovasc Surg. 1996;4:389-392.
18. Chervu A, Moore WS, Gelabert HA, et al. Prevention of graft infection by use of prostheses bonded with a rifampin collagen release system. J Vasc Surg. 1991;14:521-524.
19. Veenstra DL, Saint S, Saha S, et al. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection. JAMA. 1999;281:261-267.
20. Balaban N, Goldkorn T, Nhan RT, et al. Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science. 1998;280:438-440.
21. Balaban N, Gov Y, Bitler A, et al. Prevention of Staphylococcus aureus biofilm on dialysis catheters and adherence to human cells. Kidney Int. 2003;63:340-345.
22. Balaban N, Collins LV, Cullor JS, et al. Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. Peptides. 2000;21:1301-1311.
23. Balaban N, Goldkom T, Gov Y, et al. Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating protein (TRAP). J Biol Chem. 2001;276:2658-2667.
24. Balaban N, Giacometti A, Cirioni O, et al. Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J Infect Dis. 2003;187:625-630.
25. Gov Y, Bitler A, Dell'Acqua G, et al. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus: structure and function analysis. Peptides. 2001;22:1609-1620.
26. Bevins CL, Zasloff M. Peptides from frog skin. Annu Rev Biochem. 1990;59:395-414.
27. Simmaco M, Mignogna G, Barra D. Antimicrobial peptides from amphibian skin: what do they tell us? Biopolymers. 1998;47:435-450.
28. Simmaco M, Mignogna G, Canofeni S, et al. Temporins, antimicrobial peptides from the European red frog Rana temporario. Eur J Biochem. 1996;242:788-792.
29. Zhao H, Rinaldi AC, Di Giulio A, et al. Interactions of the antimicrobial peptides temporins with model biomembranes: comparison of temporins B and L. Biochemistry. 2002;41:4425-4436.
30. Harjunpaa I, Kuusela P, Smoluch MT, et al. Comparison of synthesis and antibacterial activity of temporin A. FEBS Lett. 1999;449:187-190.
31. Wade D, Silberring J, Soliymani R, et al. Antibacterial activities of temporin A analogs. FEBS Lett. 2000;479:6-9.
32. Bergamini TM, Corpus RA Jr, Brittian KR, et al. The natural history of bacterial biofilm graft infection. J Surg Res. 1994;56:393-396.
33. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Wayne, Pa: National Committee for Clinical Laboratory Standards; 2001. Approved standard M7-A5.
34. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility test. 7th ed. Wayne, Pa: National Committee for Clinical Laboratory Standards; 2001. Approved standard M2-A7.
35. Gristina AG, Hobgood CD, Webb LX, et al. Adhesive colonization of biomaterials and antibiotic resistance. Biomaterials. 1987;8:423-426.
36. O'Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol. 2000;54:49-79.
37. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin. J Antimicrob Chemother. 1997;40:135-136.
38. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med. 1987;316:927-931.
39. Schroeder JM. Epithelial antimicrobial peptides: innate local host response elements. Cell Mol Life Sci. 1999;56:32-46.
40. Yang D, Biragyn A, Kwak LW, et al. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 2002;23:291-296.
41. Hancock REW, Scott MG. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci U S A. 2000;97:8856-8861.
42. Ghiselli R, Giacometti A, Cirioni O, et al. Temporin A as prophylactic agents against methicillin-susceptible and methicillin-resistant Staphylococcus epidermidis vascular graft infection. J Vasc Surg. 2002;36:1-4.